(HealthDay)—Gliptin treatment is associated with increased acute pancreatitis risk, according to research published online Sept. 22 in Diabetes Care.
Sep 27, 2016
0
1
An approach that could reduce the chances of drugs failing during the later stages of clinical trials has been demonstrated by a collaboration between the University of Cambridge and pharmaceutical company GlaxoSmithKline ...
Jun 1, 2016
0
53
UK researchers have presented a new study that supports the cardiovascular safety of calcium and vitamin D supplementation. The study was based on analysis of the UK Biobank, a very large study comprising 502,664 men and ...
Apr 16, 2016
1
8
(HealthDay)—For subjects at risk of aspirin-associated upper gastrointestinal (UGI) events, long-term PA32540 (enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) appears to be safe, according to a study ...
Mar 15, 2016
0
0
The cardiovascular safety of the obesity treatment naltrexone-bupropion remains uncertain because of the unanticipated early termination of a trial to determine its safety, according to a study appearing in the March 8 issue ...
Mar 8, 2016
0
0
The drugmaker Merck is paying $830 million to resolve a federal class-action lawsuit involving shareholders and the painkiller Vioxx, which was pulled from the market years ago over safety concerns.
Jan 15, 2016
0
0
In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the ...
Aug 31, 2015
0
10
Patients with type-2 diabetes and cardiovascular disease can safely take the antihyperglycemic drug sitagliptin without an increased risk of cardiovascular complications - even if they have a history of heart failure - a ...
Aug 31, 2015
0
6
An international, multidisciplinary team including investigators from Brigham and Women's Hospital (BWH) has found that lixisenatide, a member of a class of glucose-lowering drugs frequently prescribed in Europe to patients ...
Jun 8, 2015
0
7
(HealthDay)—Movantik (naloxegol) has been approved by the U.S. Food and Drug Administration to treat opioid-induced constipation, the agency said Tuesday.
Sep 16, 2014
0
0
